Clinical Study Evaluating Safety of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy

ConditionEpilepsy
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorMostafa Bahaa

About this trial

Epilepsy is a chronic neurological disorder affecting millions of people all over the world. Epileptic seizures are caused by abnormal synchronized electrical neuronal discharges that could be either focal or widespread. Pathogenesis of epilepsy involves multiple processes including genetics, oxidative stress, ion channels, neuroinflammation, and cellular damage through autophagy and apoptosis.

Neuroinflammation is considered one of the most important factors contributing critically to epileptogenesis.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Phenytoin
  • Pentoxifylline 400 MG
  • Celecoxib 200mg

Treatment groups

90 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Mostafa Bahaa

Lead sponsor

Tanta University

Sponsor institution

Tanta University

Collaborator

Principal Investigator Maha Ahmed Younis, PhD Pharmacy Practice Department- Horus University

Collaborator